Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/65—One oxygen atom attached in position 3 or 5
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Definitions

• the active anticoccidial agents of the present invention are compounds represented by the general formula:
• R is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy
• R is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy
• R is a member of the group consisting of hydrogen and lowerjalkenoxycarbonyl.
• Suitable lower alkyl and lower alkoxy radicals are those having from 1-6 carbon atoms.
• the substituents represented by the symbol R may be one or more of the 6, 7, or 8 positions only of the quinazolinone nucleus. 7
• Coccidiosis has been recognized as one of the most important diseases confronting the poultry industry, nevertheless, heretofore, no entirely satisfactory method of control of the disease has been provided. This is evidenced by the fact that losses in the United States due to poultry coccidia are estimated to exceed 38 million dollars annually. Coccidiosis is also an important disease of sheep, goats, cattle, rabbits, etc.
• the active coccidiostat is normally first compounded into an animal feed supplement.
• These supplements which contain relatively large percentage of the coccidiostat, are then uniformly distributed in the finished animal feed either directly or after an intermediate processing step.
• the feed supplements are prepared by adding the subject compounds to a suitable carrier and mixing for sufficient time to give substantially uniform dispersion of the coccidiostat in the carrier.
• These supplements ordinarly contain about 0.1-1.0% and preferably from about 03-06% of active ingredient.
• the carrier or diluent is a solid edible material that is inert with respect to the subject compounds and that may be administered with safety to the animals to be treated.
• Typical of such carriers are distillers grains, corn meal, ground oyster shells, attapulgus clay, molasses solubles, antibiotic mycelia, soya grits, soyabean feed, soyabean meal, crushed limestone and the like.
• fats, oils, antioxidants, and surface active agents can be employed.
• anticoccidials may be combined with other anticoccidials such as the sulfonamides, or withfeed additives, such as antibiotics, vitamins, etc. 7
• the formulation used was as follows:
• the medicaments employed in the instant tests were 4(3H)-quinazolinone, 6,8-dichlor-3-[3-(3-hydroxy-2- piperidyl)-acetonyl]-, hydrochloride; 4(3H)-quinazolinone, 6-phenyl-3-[3-(3-hydroxy 2 piperidyl)acetonyl]-, dihydrochloride and 4(3H)-quinazolinone, 7-bromo-6-chloro- 3- 3-( 3 -hydroxy-2-piperidyl) acetonyl] hydrobromide.
• the medicated and unmedicated diets were presented to the chicks and the chicks were permitted to feed and drink ad libitum from two days prior until 7 days following the oral inoculation with sporulated o0cysts of Eimeria tenella.
• the number of o0cysts inoculated directly into the crops of all chicks in the test was sufficient to produce 85100% mortality in the untreated controls.
• the quantity necessary to produce this mortality rate was determined prior to the time of inoculation by giving graded quantities of o0cysts to comparable birds. Seven days following inoculation the test was terminated and the mortality rate recorded for each group.
• Example 5 -E. acervu1inaPr0phylactic In determining the eflicacy of the compounds against the infective organism E. acervulina (one of the etiological agents causing intestinal coccidiosis in chickens), 200 Rhode Island Red male x Barred Rock female cross TABLE III.E. NEC'ATRIX-PROPHYLACTIC Parts per Number Number Avg. per- Gompound million birds Percent with cent wt.
• the chicks were permitted to feed ad libitum throughout the entire test. Two days after presentation of the test feeds all chicks were inoculated with approximately 150,000 sporulated oocysts of the organism E. maxima. Ten days after inoculation the chicks were removed from their cages, weighed, the Weights recorded,
• Example 12 Preparati0n of 6,7,8-trichl0ro-3-[3-(I-allyloxycarbonyl 3 methoxy 2 piperidyl)acetonyl]- 4 (3H) -quinazolinone 6,7,8-tr'ichloro-4(3H)-quinazolinone (1.5 grams) is partially dissolved in 7.3 ml. of 1.1 N sodium methoxide. To this is added 2.0 grams of allyl-2-(3-bromoacetonyl)- 3-methoXyl-1-piperidine carboxylate dissolved in 18 ml. of methanol. The mixture is stirred at room temperature for 4 hours.
• Example 13 Preparati0n of 6,7,8-trichlor0-3- [3 (3-hydroxy 2 piperidyl) acetonyl] 4 (3H) quinazolinone hydrobromia'e
• the product from Example 12 is dissolved in 75 ml. of 48% hydrobromic acid and heated at reflux for 1 hour. The solution is evaporated under vacuum to dryness. The residue is heated for 30 minutes in refluxing 2/3-ethanol (remains undissolved), then collected by filtration; yield 0.85 gram (29%) of crude product. Recrystallization from ethanol-water (activated charcoal) gives White crystals, melting point 239 dec.
• Example 10 Preparatl0n of allyl-Z-(3-bromoacet0nyl)- 3-methoxy-l -piperidine carboxylate This compound is prepared by the method of B. R. Baker and F, J. McEvoy, J. Org. Chem. 20, 141 (1955), using .2-acetonyl-3-methoxypiperidine synthesized as described in the Barringer and Berkelhammer copending application filed concurrently herewith.
• Example 11 Preparati0n of 6,7,8-trichl0r0-4 (3H) quinazolinone 3,4,5-trichloroanthranilic acid (8.6 grams) and 6.3 grams of .forrnamide are dissolved in 20 ml. of dimethylformamide. The solution is heated at reflux for 16 hours. The product crystallizes upon cooling, is collected by filtration, and washed with ethanol.
• Example 21 Preparati0n of 6,7-dichl0r0-3-[3-(3-acetoxy-Z-piperidyl) acetonyl] 4 (3H) -quinaz0lin0ne
• Thionyl chloride (1 ml.) is added to 400 mg. of 6,7-dichloro 3 [3 (3 hydroxy 2-piperidyl)acetonyl]-4(3H)- quinazolinone hydrobromide suspended in a mixture of 1 ml. of acetic anhydride and 1 ml. of glacial acetic acid. A homogeneous solution is formed accompanied by vigorous evolution of sulfur dioxide.
• the white crystalline product precipitates upon standing, is removed by filtration, and is washed with ether.
• the ether-washed solid is dissolved in chloroform and the solution washed thoroughly with aqueous sodium carbonate.
• the chloroform layer is separated, dried, and evaporated under vacuum, yielding an oil which separates as a white crystalline 12 solid (60 mg.) M.P. ISO-151 after solution in refluxing hexane-acetone and cooling.
• Example 22 Preparati0n of 6,8-dii0d0-3-[3-(1-allyl0xycarbonyl 3 methoxy 2 piperidyl)acet0nyl] 4 (3H) quirzazolinone
• the procedure of Example 12 is followed, using 2.39 grams of 6,8-diiodo-4(3H)-quinazolinone [M. R. Subbaram, J. Madras Uni., 24B, 179-82 (1954); C. A. 50, 352a (1956)] and 2.0 grams of allyl-2-(3-bromoacetonyl)-3-methoxy-1-piperidine carboxylate.
• Example 23 -Preparati0n of 6,8-dii0d0-3-[3-(3-hydr0xy- 2 piperidyl)acet0nyl] 4(3H) quinazolinone hydrabromide
• the product of Example 22 is hydolyzcd according to the procedure of Example 13. 250 mg. of white crystalline product is obtained, melting point 244 C. dec.
• Example 24 Preparati0n of 6-nitr0-3-[3-(1-allyl0xycarbonyl 3 methoxy 2 piperidyl)acet0nyl] 4(3H)- quinazolinone
• the procedure of Example 12 is followed, using 1.15
• the product is a viscous brown syrup.
• Example 25 Preparati0m of 6-nitr0-3-[3-(3-hydroxy-2- piperidyl)acet0nyl] -4 (3H )-quinazolin0ne hydrochloride
• the product from Example 24 is hydrolyzed according to the procedure of Example 13.
• the residue remaining from the removal of the hydrobromic acid is treated with refluxing saturated ethanolic hydrochloric acid for 30 minutes and the resultant solid filtered ofl and dissolved in aqueous ethanol.
• the ethanolic solution is heated under reflux for 30 minutes, treated with decolorizing carbon, and filtered. Refrigeration of the filtrate gives 610 mg. of the hydrochloride salt as pale yellow crystals, melting point 215 dec.
• Example 26 Preparation of 6,8-dibrom0-4 (3H )-qainazolinone The procedure of Example 11 is followed, using 0.9 gram of formamide and 2.95 grams of 3,5-dibromoanthranilic acid in 10 cc. of dimethylformamide. The product is purified by slurrying in hot ethanol and filtered to give 2.45 grams (82%) of pale yellow needles, unmelted at 300.
• Example 27 Preparation of 6,8-dibrom0-3-[3-(1-allyloxycarbonyl 3-meth0xy-2-piperidyl) acetonyl]-4 (3H quinazolinone
• the procedure of Example 12 is followed, using 1.82 grams of 6,8 dibromo 4(3H)-quinazolinone and 2.0 grams of allyl-2-(3-bromoacetonyl)-3-methoxy-1-piperidine carboxylate, except that no excess sodium methoxide is used.
• the product is a dark brown syrup.
• Example 28 Preparati0n 0f 6,8-dibrom0-3-[3-(3-hydroxy 2-piperidyl)acel0nyl ]-4 (3H )-quinaz0lin0ne hya'robromide
• the product of Example 27 is heated under reflux with 30 cc. of 6 N hydrochloric acid for 1 hour and the solution evaporated to dryness.
• the residue is dissolved in 20 cc. of 48% hydrobromic acid and the solution heated under reflux for 30 minutes and evaporated to dryness.
• the brown residue is treated with boiling saturated ethanolic hydrochloric acid for 20 minutes, and the resulting solid collected by filtration.
• the material is subject to rehydrolysis following the procedure of Example 13. 360 mg. of the crystalline hydrobromide is obtained, melting point 250 dec.
• Example 29 -Preparatin of 6-flu0r0-4(3H)-quinazolinone
• the procedure of Example 11 is followed, using 2 cc. of formamide and 1.1 grams of S-fluoroanthranilic acid in 3 cc. of dimethylformamide. Recrystallization of the crude mass from 95% ethanol gives 550 mg. of colorless product, melting point 249-251".
• Example 32 The citrate salt of 6-chloro-3-[3-(3-hydroxy-2-piperidyl)acetonyl]-4(3H)-quinazolinone is obtained by taking up the 336 mg. of the free base of this compound (see Example 19) in ethanol and adding an ethanolic solution of 192 mg. of citric acid. Evaporation of the solvent gives the white crystalline citrate.
• Example 33 Preparati0n of 8-br0mo-6-chl0r0-3-[3-(1- allyloxycarbonyl 3 melhoxy-Z-piperidyl)acetonyl]-4 (3H) -quinaz0lin0ne
• the procedure of Example 12 is followed, using 3.1 grams of 8-bromo-6-chloro-4(3H)-quinazolinone and 4.0 grams of allyl-2-(3-bromoacetonyl)-3-methoxy-1-piperidine carboxylate.
• the product is a viscous amber oil.
• Example 34 Preparation of 8-br0m0-6-chl0r0-3-[3-(3- hydroxy 2 piperidyl)acetonyl]-4(3H)-qu'inaz0lin0ne hydrobromide
• the product of Example 33 is hydrolyzed following the procedure of Example 13. A white crystalline product is obtained, melting point 250 dec.
• Example 35 --Preparation of 6-br0m0-8-Chl0r0-3-[3-(1- allyloxycarbonyl 3 methoxy 2-piperidyl)acet0nyl]- 4 (3H )-quinaz0 lin0ne
• the procedure of Example 12 is followed, using 1.55 grams of 6-bromo-8-chloro-4(3H)-quinazolinone and 2.0 grams of allyl 2-(3-bromoacetonyl)-3-methoxy-1-piperidine carboxylate. 2.5 grams (85%) of product is obtained as a viscous amber oil.
• Example 3 6 -Prcparati0nv of 6-br0m0-8-ch l0r0-3- [3- (3- hydroxy 2 piperidyl acetonyl] -4 (3H -quinaz0lin0ne h ydrobromid e
• the product of Example 35 is hydrolyzed following the procedure of Example 13. 0.8 gram of crude product is obtained which recrystallizes from ethanol-water (activated charcoal) as a white crystalline material, melting point 251 dec.
• Example 3 7 Preparatiom of 6-b1'0m0-7-chI0r0-4 (3H quinazolz'none 4-chloroanthranilic acid (17.2 grams) is dissolved in 100 ml. of p-dioxane. After heating the solution to 60,
• Example 39 Prepanati0n 0f 6-br0m0-7-chl0r0-3-[3-(3- hydroxy 2 piperidyl) acetonyl] -4 (3H )-quinazolin0ne hydrobromide
• the product of Example 38 is hydrolyzed following the procedure of Example 13. A white crystalline product is obtained, melting point 242 dec.
• Example 40 Preparation 0 7-br0m0-6-chl0r0-4 (3H quinazolinone 6-bromoisatin (12.0 grams) is dissolved in 300 ml. of glacial acetic acid, heated to and 10 ml. of sulfuryl chloride added. After 30 minutes the solution is cooled to 20, causing 7.2 grams (55%) of 6-bromo-5-chloroisatin to separate as deep red crystals, melting point 284- 285. The isatin is oxidized with 30% hydrogen peroxide in N NaOH giving 5.8 grams (84%) of 5-bromo-4-chloroanthranilic acid as tan crystals, melting point 251-252".
• Example 41 -Preparati0n of 7-b'r0m0-6-chl0r0-3-[3-(1- allyloxycarbonyl 3 metlioxy 2 piperidyl) acetonyl ⁇ 4 (3H) -quinazolin0ne
• the procedure of Example 12 is followed using 2.95 grams of 7-bromo-6-chloro-4(3H)-quinazolinone and 3.34 grams of allyl-2- 3-bro1noacetonyl) -3methoxy-l-piperidine carboxylate.
• the product is a brown syrup.
• Example 44 Preparation of 6,7-dibr0m0-3- [3- (l-allyloxycarbonyl 3-meth0xy-2-piperidyl acetonyl] -4 (3H quinazolinone
• the procedure of Example 12 is followed using 2.3 grams of 6,7-dibrorno-4(3H)-quinazolinone and 5 .0 grams of allyl-2- 3-bromoacetonyl) -3-methoxy-1-piperidine carboxylate.
• the product is a dark brown syrup.
• Example 49 Preparati0n of 6-chlofi0-7-fluor0-3-[3-(3- hydroxy 2 piperidyl)acet0nyl]-4(3H)-quinaz0lin0ne hydrobromia'e
• the product of Example 48 is hydrolyzed according to the procedure of Example 13. Evaporation of the hydrobromic acid leaves a residue from which 1.75 g. of brown solid is obtained after several treatments with boiling absolute alcohol. Recrystallization from alcohol-water gives 650 mg. of solid, melting point 237 dec.
• R is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy
• R is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy
• R is a member ⁇ of the group consisting of hydrogen and lower alkenoxycarbonyl, and the physiologically acceptable salts thereof.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Fodder In General (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (7)

Applications Claiming Priority (1)

Publications (1)

Family

ID=23515259

Family Applications (1)

Country Status (7)

Cited By (48)

Families Citing this family (1)

• 1964
  • 1964-07-20 US US383910A patent/US3320124A/en not_active Expired - Lifetime
• 1965
  • 1965-06-11 IL IL23717A patent/IL23717A/xx unknown
  • 1965-06-23 GB GB26625/65A patent/GB1087015A/en not_active Expired
  • 1965-07-19 BR BR171429/65A patent/BR6571429D0/pt unknown
  • 1965-07-20 ES ES0315612A patent/ES315612A1/es not_active Expired
  • 1965-07-20 DE DE1965A0049791 patent/DE1545551B2/de active Granted
  • 1965-07-20 FR FR1550956D patent/FR1550956A/fr not_active Expired

Non-Patent Citations (1)

Also Published As

Similar Documents